Loading
A phase 3 trial of benmelstobart and anlotinib in lung cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., not yet recruiting.
A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients is a phase 3, randomised interventional study registered as NCT06469879 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with a registry enrolment figure of 358 participants, started 2024-09 and due to reach its primary completion in 2026-09. Interventions recorded: TQB2450+Anlotinib; TQB2450 placebo + Anlotinib placebo. Conditions listed: Small Cell Lung Cancer Limited Stage. Primary outcome: Progression-free survival (PFS) evaluated by the Independent Review Committee (IRC). Lung eligibility wording from the registry: "* Pathologically confirmed patients with limited stage small cell lung cancer (according to the Veterans Administration Lung Study Group (VALG) stage);". Sites: China. No results are recorded here; the registry entry is the source.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Limited-stage small-cell lung cancer, Anti-angiogenic therapy and the tag lung-deep-dive.
Shares Benmelstobart, Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.